Ads
related to: liver damage caused by chemotherapy treatment pictures of human anatomywiserlifestyles.com has been visited by 100K+ users in the past month
Search results
Results From The WOW.Com Content Network
Liver damage can be caused by viruses, alcohol, medications, and other hepatotoxins. [12] Acetaminophen, found in many prescription and over-the-counter medications, is the most common drug that can cause liver damage if taken in a high dose or in conjunction with alcohol. [12] Many liver transplant patients require the transplant because of ...
Hepatic arterial infusion (HAI) is a medical procedure that delivers chemotherapy directly to the liver.The procedure, mostly used in combination with systemic chemotherapy, plays a role in the treatment of liver metastases in patients with colorectal cancer (CRC). [1]
A liver metastasis is a malignant tumor in the liver that has spread from another organ that is affected by cancer. The liver is a common site for metastatic disease because of its rich, dual blood supply (the liver receives blood via the hepatic artery and portal vein). Metastatic tumors in the liver are 20 times more common than primary liver ...
The liver damage can consist of damage to liver cells, hepatic sinusoidal syndrome (obstruction of the veins in the liver), cholestasis (where bile does not flow from the liver to the intestine) and liver fibrosis. [127] [128] Nephrotoxicity (kidney damage) can be caused by tumor lysis syndrome and also due direct effects of drug clearance by ...
Treatment generally includes supportive care including pain management and possibly diuretics. [5] In those with severe disease due to a bone marrow transplant, defibrotide is a proposed treatment. [6] It has been approved for use in severe cases in Europe and the United States. [7] [8] A placebo controlled trial, however, has not been done as ...
Mipsagargin (G-202), has orphan drug designation as a treatment during chemotherapy for HCC. [93] It is a thapsigargin-based prodrug with cytotoxic activity used to reduce blood flow to the tumor during treatment. Results from Phase 2 trial recommended G-202 as a first-in-class PSMA-targeted prodrug and that it move to clinical trials. [94]